{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:28:06Z","timestamp":1784561286798,"version":"3.55.0"},"reference-count":69,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,7]],"date-time":"2024-01-07T00:00:00Z","timestamp":1704585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Nosocomial central nervous system (CNS) infections with carbapenem- and colistin-resistant Gram-negative and vancomycin-resistant Gram-positive bacteria are an increasing therapeutic challenge. Here, we review pharmacokinetic and pharmacodynamic data and clinical experiences with new antibiotics administered intravenously for the treatment of CNS infections by multi-resistant bacteria. Cefiderocol, a new siderophore extended-spectrum cephalosporin, pharmacokinetically behaves similar to established cephalosporins and at high doses will probably be a valuable addition in our therapeutic armamentarium for CNS infections. The new glycopeptides dalbavancin, telavancin, and oritavancin are highly bound to plasma proteins. Although effective in animal models of meningitis, it is unlikely that they reach effective cerebrospinal fluid (CSF) concentrations after intravenous administration alone. The \u03b2-lactam\/\u03b2-lactamase inhibitor combinations have the principal problem that both compounds must achieve adequate CSF concentrations. In the commercially available combinations, the dose of the \u03b2-lactamase inhibitor tends to be too low to achieve adequate CSF concentrations. The oxazolidinone tedizolid has a broader spectrum but a less suitable pharmacokinetic profile than linezolid. The halogenated tetracycline eravacycline does not reach CSF concentrations sufficient to treat colistin-resistant Gram-negative bacteria with usual intravenous dosing. Generally, treatment of CNS infections should be intravenous, whenever possible, to avoid adverse effects of intraventricular therapy (IVT). An additional IVT can overcome the limited penetration of many new antibiotics into CSF. It should be considered for patients in which the CNS infection responds poorly to systemic antimicrobial therapy alone.<\/jats:p>","DOI":"10.3390\/antibiotics13010058","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T06:12:58Z","timestamp":1704694378000},"page":"58","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections"],"prefix":"10.3390","volume":"13","author":[{"given":"Roland","family":"Nau","sequence":"first","affiliation":[{"name":"Department of Neuropathology, University Medicine G\u00f6ttingen, Georg-August-University G\u00f6ttingen, 37075 G\u00f6ttingen, Germany"},{"name":"Department of Geriatrics, Protestant Hospital G\u00f6ttingen-Weende, 37075 G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Seele","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, University Medicine G\u00f6ttingen, Georg-August-University G\u00f6ttingen, 37075 G\u00f6ttingen, Germany"},{"name":"Department of Geriatrics, Protestant Hospital G\u00f6ttingen-Weende, 37075 G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Eiffert","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, University Medicine G\u00f6ttingen, Georg-August-University G\u00f6ttingen, 37075 G\u00f6ttingen, Germany"},{"name":"Amedes MVZ for Laboratory Medicine, Medical Microbiology and Infectiology, 37077 G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1177\/1060028020932513","article-title":"Treatment Considerations for CNS Infections Caused by Vancomycin-Resistant Enterococcus faecium: A Focused Review of Linezolid and Daptomycin","volume":"54","author":"Lee","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_2","first-page":"e15398","article-title":"Experience with enterococcal meningitis\/ventriculitis in children","volume":"65","author":"Alabaz","year":"2022","journal-title":"Pediatr. Int."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Shi, J., Sun, T., Cui, Y., Wang, C., Wang, F., Zhou, Y., Miao, H., Shan, Y., and Zhang, Y. (2020). Multidrug resistant and extensively drug resistant Acinetobacter baumannii hospital infection associated with high mortality: A retrospective study in the pediatric intensive care unit. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-05321-y"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Fursova, N.K., Fursov, M.V., Astashkin, E.I., Fursova, A.D., Novikova, T.S., Kislichkina, A.A., Sizova, A.A., Fedyukina, G.N., Savin, I.A., and Ershova, O.N. (2023). Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Causing Nosocomial Meningitis in the Neurological Intensive Care Unit. Microorganisms, 11.","DOI":"10.3390\/microorganisms11082020"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e00190-19","DOI":"10.1128\/CMR.00190-19","article-title":"Intrathecal Antibacterial and Antifungal Therapies","volume":"33","author":"Nau","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Muller, A.E., van Vliet, P., and Koch, B.C.P. (2023). Clinical Experience with Off-Label Intrathecal Administration of Selected Antibiotics in Adults: An Overview with Pharmacometric Considerations. Antibiotics, 12.","DOI":"10.3390\/antibiotics12081291"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Haddad, N., Carr, M., Balian, S., Lannin, J., Kim, Y., Toth, C., and Jarvis, J. (2022). The Blood-Brain Barrier and Pharmacokinetic\/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults. Antibiotics, 11.","DOI":"10.3390\/antibiotics11121843"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Karvouniaris, M., Almyroudi, M.P., Abdul-Aziz, M.H., Blot, S., Paramythiotou, E., Tsigou, E., and Koulenti, D. (2023). Novel Antimicrobial Agents for Gram-Negative Pathogens. Antibiotics, 12.","DOI":"10.3390\/antibiotics12040761"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S552","DOI":"10.1093\/cid\/ciz828","article-title":"Pharmacokinetic and pharmacodynamic profiles of Cefiderocol, a novel siderophore cephalosporin","volume":"69","author":"Katsube","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","unstructured":"(2023, December 25). European Medicines Agency EMA (2021): ANNEX I. SUMMARY OF PRODUCT CHARACTERISTICS CEFIDEROCOL. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fetcroja-epar-product-information_en.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jgar.2022.11.019","article-title":"Intravenous cefiderocol for neurosurgical meningitis from an extensively drug-resistant New-Delhi metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa strain","volume":"32","author":"Stevenson","year":"2023","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"dlab188","DOI":"10.1093\/jacamr\/dlab188","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Meschiari","year":"2021","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1093\/jac\/dkac248","article-title":"Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis","volume":"77","author":"Kufel","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"ofac391","DOI":"10.1093\/ofid\/ofac391","article-title":"Using Cefiderocol: A Case Report and Literature Review","volume":"9","author":"Marcelo","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/jac\/dkac066","article-title":"Cerebrospinal fluid concentrations of cefiderocol during the treatment of extensively drug-resistant Pseudomonas aeruginosa ventriculitis","volume":"77","author":"Bennis","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","first-page":"454","article-title":"Treatment with cefiderocol in K. pneumoniae KPC nosocomial external ventricular drainage meningitis: A brief report","volume":"30","author":"Colombo","year":"2022","journal-title":"Infez. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6311","DOI":"10.1128\/AAC.03572-14","article-title":"Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic\/pharmacodynamic target","volume":"58","author":"Lepak","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: A novel cephalosporin\/\u03b2-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jgar.2023.04.017","article-title":"In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020","volume":"33","author":"Hawser","year":"2023","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e00275-18","DOI":"10.1128\/AAC.00275-18","article-title":"Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits","volume":"62","author":"Petraitis","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e01174-18","DOI":"10.1128\/AAC.01174-18","article-title":"Randomized, Double-Blind, Placebo-Controlled Studies of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Eravacycline","volume":"62","author":"Newman","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Rusu, A., and Buta, E.L. (2021). The Development of Third-Generation Tetracycline Antibiotics and New Perspectives. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122085"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3390\/idr13030076","article-title":"Inadequate Cerebrospinal Fluid Concentrations of Available Salvage Agents Further Impedes the Optimal Treatment of Multidrug-Resistant Enterococcus faecium Meningitis and Bacteremia","volume":"13","author":"Wenzler","year":"2021","journal-title":"Infect. Dis. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40262-021-01088-w","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin","volume":"61","author":"Molina","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_26","first-page":"49","article-title":"Telavancin: A novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens","volume":"4","author":"Das","year":"2017","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1128\/AAC.50.2.770-773.2006","article-title":"Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters","volume":"50","author":"Stucki","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1128\/AAC.45.7.2169-2172.2001","article-title":"Activity of LY333328 in Experimental Meningitis Caused by a Streptococcus pneumoniae Strain Susceptible to Penicillin","volume":"45","author":"Gerber","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1128\/AAC.47.6.1907-1911.2003","article-title":"Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis","volume":"47","author":"Cabellos","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"104420","DOI":"10.1016\/j.yrtph.2019.104420","article-title":"Comparative pharmacokinetics of tedizolid in rat plasma and cerebrospinal fluid","volume":"107","author":"Gu","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1128\/AAC.00515-06","article-title":"Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains","volume":"51","author":"Beer","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/AAC.26.5.730","article-title":"Penetration of aztreonam into cerebrospinal fluid of patients with and without inflamed meninges","volume":"26","author":"Duma","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1128\/AAC.40.3.763","article-title":"Cerebrospinal fluid ceftazidime kinetics in patients with external ventriculostomies","volume":"40","author":"Nau","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1128\/AAC.41.5.987","article-title":"Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients","volume":"41","author":"Nau","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1128\/AAC.42.8.2012","article-title":"Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy","volume":"42","author":"Nau","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Gorham, J., Taccone, F.S., and Hites, M. (2022). Drug Regimens of Novel Antibiotics in Critically Ill Patients with Varying Renal Functions: A Rapid Review. Antibiotics, 11.","DOI":"10.3390\/antibiotics11050546"},{"key":"ref_37","unstructured":"EUCAST 2021 (2023, October 25). The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 11.0. Available online: http:\/\/www.eucast.org."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s10096-023-04647-0","article-title":"Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland","volume":"42","author":"Nordmann","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e01698-20","DOI":"10.1128\/AAC.01698-20","article-title":"Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain","volume":"65","author":"Sime","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e00115-20","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-Lactam-\u03b2-Lactamase Inhibitor Combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ijantimicag.2017.04.001","article-title":"Use of ceftolozane\/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa","volume":"49","author":"Dinh","year":"2017","journal-title":"Int. J. Antimicrob. Agents."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s15010-020-01539-9","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: Three cases and a review of the literature","volume":"49","author":"Meschiari","year":"2021","journal-title":"Infection"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s15010-020-01510-8","article-title":"Continuous infusion of ceftolozane-tazobactam resulted in high cerebrospinal fluid concentrations of ceftolozane in a patient with multidrug-resistant Pseudomonas aeruginosa meningitis","volume":"49","author":"Winans","year":"2021","journal-title":"Infection"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"ofaa549","DOI":"10.1093\/ofid\/ofaa549","article-title":"Plasma and Cerebrospinal Fluid Therapeutic Drug Monitoring of Ceftolozane and Tazobactam During Treatment of Multidrug-Resistant Pseudomonas aeruginosa Meningitis","volume":"7","author":"McCreary","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/IDR.S326456","article-title":"Current Perspectives on the Diagnosis and Management of Healthcare-Associated Ventriculitis and Meningitis","volume":"15","author":"Karvouniaris","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00003088-199426020-00003","article-title":"Clinical pharmacokinetics of aztreonam. An update","volume":"26","author":"Mattie","year":"1994","journal-title":"Clin. Pharmacokinet."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"faa349","DOI":"10.1093\/ofid\/ofaa349","article-title":"Using Therapeutic Drug Monitoring to Treat KPC-Producing Klebsiella pneumoniae Central Nervous System Infection with Ceftazidime\/Avibactam","volume":"7","author":"Yasmin","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.2147\/IDR.S403527","article-title":"Ceftazidime-Avibactam Treatment for Severe Post-Neurosurgical Meningitis and Abscess Caused by Extended-Spectrum \u03b2-Lactamase Escherichia coli in a Pediatric Patient: A Case Report","volume":"16","author":"Ren","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"ref_49","first-page":"45","article-title":"Carbapenem treatment of meningitis","volume":"96","author":"Klugman","year":"1995","journal-title":"Scand. J. Infect. Dis. Suppl."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Hilbert, D.W., DeRyke, C.A., Motyl, M., Hackel, M., and Young, K. (2023). Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: Analysis of global SMART 2018-2020. BMC Microbiol., 23.","DOI":"10.1186\/s12866-023-02864-3"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2165\/00003088-200039030-00002","article-title":"Comparative pharmacokinetics of the carbapenems: Clinical implications","volume":"39","author":"Mouton","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"ref_52","first-page":"669","article-title":"Studien \u00fcber die Aufnahme der Anilinfarben durch die lebende Zelle","volume":"34","author":"Overton","year":"1900","journal-title":"Jahrb. Wiss. Bot."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1007\/BF01466734","article-title":"Protein size and cerebrospinal fluid composition","volume":"52","author":"Felgenhauer","year":"1974","journal-title":"Klin. Wochenschr."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12974-022-02538-3","article-title":"Spatial and temporal variation of routine parameters: Pitfalls in the cerebrospinal fluid analysis in central nervous system infections","volume":"19","author":"Djukic","year":"2022","journal-title":"J. Neuroinflamm."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.expneurol.2015.02.032","article-title":"A balanced view of choroid plexus structure and function: Focus on adult humans","volume":"267","author":"Spector","year":"2015","journal-title":"Exp. Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1124\/dmd.113.055335","article-title":"Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential","volume":"42","author":"Vishwanathan","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijpharm.2017.12.037","article-title":"OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam","volume":"537","author":"Wen","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2174\/1389200223666220428081109","article-title":"Interactions Between Meropenem and Renal Drug Transporters","volume":"23","author":"Dong","year":"2022","journal-title":"Curr. Drug Metab."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/jac\/dkz101","article-title":"Role of transporters in the disposition of a novel \u03b2-lactamase inhibitor: Relebactam (MK-7655)","volume":"74","author":"Chan","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1128\/AAC.6.4.437","article-title":"Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives","volume":"6","author":"Dacey","year":"1974","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1128\/AAC.40.1.218","article-title":"High doses of cefotaxime in treatment of adult meningitis due to Streptococcus pneumoniae with decreased susceptibilities to broad-spectrum cephalosporins","volume":"40","author":"Viladrich","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e0082022","DOI":"10.1128\/aac.00820-22","article-title":"Penicillin- and Cephalosporin-Resistant Pneumococcal Meningitis: Treatment in the Real World and in Guidelines","volume":"66","author":"Cabellos","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Kerz, T., von Loewenich, F.D., Roberts, J., Neulen, A., and Ringel, F. (2018). Cerebrospinal fluid penetration of very high-dose meropenem: A case report. Ann. Clin. Microbiol. Antimicrob., 17.","DOI":"10.1186\/s12941-018-0299-0"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1128\/AAC.39.1.232","article-title":"Relationship between structure and convulsant properties of some beta-lactam antibiotics following intracerebroventricular microinjection in rats","volume":"39","author":"Ammendola","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.2147\/IDR.S416948","article-title":"Treatment of Ventriculitis and Meningitis After Neurosurgery Caused by Carbapenem-Resistant Enterobacteriaceae (CRE): A Challenging Topic","volume":"16","author":"Li","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/cid\/ciw861","article-title":"Infectious Diseases Society of America\u2019s clinical practice guidelines for healthcare-associated ventriculitis and meningitis","volume":"64","author":"Tunkel","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13613-023-01153-6","article-title":"French Intensive Care Society. Rationale and evidence for the use of new beta-lactam\/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients","volume":"13","author":"Barbier","year":"2023","journal-title":"Ann. Intensive Care."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1021\/ci700257y","article-title":"Computation of octanol-water partition coefficients by guiding an additive model with knowledge","volume":"47","author":"Cheng","year":"2007","journal-title":"J. Chem. Inf. Model."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Wardecki, D., Do\u0142owy, M., and Bober-Majnusz, K. (2023). Assessment of Lipophilicity Parameters of Antimicrobial and Immunosuppressive Compounds. Molecules, 28.","DOI":"10.3390\/molecules28062820"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/1\/58\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:41:32Z","timestamp":1760103692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/1\/58"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,7]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["antibiotics13010058"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13010058","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,7]]}}}